A Trial of HRS-1893 in Healthy Volunteers and Patients With Obstructive Hypertrophic Cardiomyopathy

Phase 1 Completed 76 enrolled Shandong Suncadia Medicine Co., Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this phase Ⅰ study is to evaluate the safety, tolerability and pharmacokinetics of HRS-1893 in healthy volunteers and patients with obstructive hypertrophic cardiomyopathy

Timeline

Start: 2023-06-05
Primary completion: 2024-03-21
Completion: 2024-03-21

Publications

Yang K, Liu W, Lin Y, Jing S, Sun X, Fu M, Li X, Zhang T, Hu M, He F, Feng J. Safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of HRS-1893, a cardiac myosin inhibitor, in healthy subjects. Br J Clin Pharmacol. 2026 May 20. doi: 10.1002/bcp.70542. Online ahead of print.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HRS-1893	Unknown	5 mg	Subcutaneous
Subject	HRS-1893	Unknown	10 mg	Subcutaneous
Subject	HRS-1893	Unknown	15 mg	Subcutaneous
Subject	HRS-1893	Unknown	20 mg	Subcutaneous
Subject	HRS-1893	Unknown	30 mg	Subcutaneous
Subject	HRS-1893	Unknown	40 mg	Subcutaneous
Subject	HRS-1893	Unknown	50 mg	Subcutaneous
Subject	HRS-1893	Unknown	60 mg	Subcutaneous
Subject	HRS-1893	Unknown	75 mg	Subcutaneous
Subject	HRS-1893	Unknown	100 mg	Subcutaneous

A Trial of HRS-1893 in Healthy Volunteers and Patients With Obstructive Hypertrophic Cardiomyopathy

Summary

Timeline

Publications

Drugs

Indications